US › Healthcare

Palisade Bio Inc (PALI)

US · Healthcare · Biotechnology

$1.70+0.59%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$500,000

Net profit

$-10.6M

EPS

$-0.05

EPS estimate

$-0.05

Net margin

-2,114.8%

EPS came in at -0.05 against a street estimate of -0.05 — a beat of 0.0%.

Key statistics

Market cap

$359.0M

P/E

3.2

Forward P/E

0.0

P/B

2.94

Book value

$0.70

EPS (TTM)

$0.65

52-week high

$2.86

52-week low

$0.55

50-day MA

$2.03

200-day MA

$1.94

Beta

1.55

Analyst view

Analysts rate Palisade Bio Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $10.22.

Shareholding

Insiders

2.15%

Institutions

101.21%

Largest institutional holders

Fund	Stake
Soleus Capital Management, L.P.	7.50%
Ameriprise Financial Inc	6.60%
B Group, Inc	6.55%
HHG PLC	6.13%
Octagon Capital Advisors LP	5.90%
Perceptive Advisors LLC	4.83%
COMMODORE CAPITAL LP	4.12%
RA Capital Management, LLC	4.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Palisade Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.